Yn. Wong et al., METABOLISM AND DISPOSITION OF EXP631 - A NOVEL ANTIDEPRESSANT ANALGESIC, Biopharmaceutics & drug disposition, 14(6), 1993, pp. 519-531
EXP631, enyl)-alpha,alpha,1-trimethyl-4-piperidinemethanol hemi-fumara
te salt (I), is a centrally acting non-opioid analgesic compound with
monoamine uptake blocking properties. EXP631 has analgesic effects in
several animal models. It is intended to be used for the treatment of
moderate to moderately severe acute and chronic pain. To characterize
the disposition of EXP631, the plasma levels of EXP631 were determined
in rats and dogs after single intravenous and oral doses. In rats, EX
P631 was rapidly absorbed following a single oral solution dose of 5-2
0 mg kg-1 with maximum plasma levels detected within 1.2 h post dose.
The absorption was complete with an oral bioavailability of 92-131%. T
he pharmacokinetics was dose independent as measured by either C(max)
or AUC values. In fasted dogs., EXP631 was absorbed rapidly and well (
F = 81%) from an oral solution with the maximum concentration detected
at 20 min post dose. In fed dogs, the absorption from capsules was sl
ower (1.38 h) compared to the solution, but the absorption was complet
e (F = 115%). An N-desmethyl metabolite (II) was found in both rat and
dog plasma samples. The structure was confirmed by mass spectroscopy,
nuclear magnetic resonance spectroscopy and comparative chromatograph
ic retention times. The metabolite is inactive as an analgesic.